

5TH WORKSHOP ON

HCV THERAPY ADVANCES

NEW ANTIVIRALS IN CLINICAL PRACTICE

AMSTERDAM, THE NETHERLANDS • 4 - 5 DECEMBER 2015

HCV THERAPY ADVANCES

New Antivirals in
Clinical Practice

Missing out on AASLD?
Join us in Amsterdam
for the update of the year
on HCV treatment!

WHY SHOULD YOU ATTEND?

It is our great pleasure to announce the fifth edition of the Workshop on **HCV Therapy Advances – New Antivirals in Clinical Practice**, to be held in Amsterdam, the Netherlands on 4 - 5 December 2015. Now that the second wave of DAAs has shown promising clinical results, it becomes very important to identify which patients benefit more from which DAA. This year's program will focus on providing clinicians with the latest information, published and presented at the AASLD in 2015, in order to give them guidance for optimal clinical management of their patients. After attending this conference,

- You will have an understanding of the basic concepts of HCV therapy as presented on AASLD
- You will be updated on the latest developments in the field of HCV antiviral research
- You will have an understanding of the challenges of HCV treatment in different patient populations
- You have received an overview of the advantages and possibilities of new antivirals in HCV therapy
- You know how to apply *Direct Acting Antivirals* in clinical practice

WHO SHOULD ATTEND?

The target audience of this workshop consists of healthcare professionals involved in daily care for HCV patients, infectious disease doctors, gastroenterologists, hepatologists and post-graduate students.

Free registration for young investigators!



PROGRAM COMMITTEE



Charles Boucher, MD, PhD
Erasmus Medical Center Rotterdam
the Netherlands



Fred Poordad, MD
University of Texas Health Science Center
USA



Stefan Zeuzem, MD
J.W. Goethe University Hospital Frankfurt
Germany

*Free registrations
for young investigators!*

PRELIMINARY PROGRAM

FRIDAY 4 DECEMBER

12.30h Lunch and Registration

Session 1: Current Treatment Options

13.30h **Approved Regimens for Non Cirrhotic Patients**

Graham Foster, PhD - Queen Mary, University of London, UK

13.50h **Approved Regimens for Cirrhotic Patients**

Marina Berenguer, MD, PhD - La Fe University Hospital Valencia, Spain (tbc)

14.10h **Next Generation Regimens**

Joost Drenth, MD, PhD - Radboud Universitair Medisch Centrum, the Netherlands

14.30h Discussion

15.00h Coffee Break

Session 2: Panel Debate (Live Webcast Session)

15.30h Moderators: **S. Zeuzem, MD & F. Poordad, MD**

Panel members to be confirmed

Session 3: Treatment Challenges in Special Population

17.00h **Renal Failure**

Rafael Esteban, MD - Hospital Valle Hebron, Spain

17.15h **Decompensated Cirrhosis**

Thomas Berg, MD - University Hospital Leipzig, Germany

17.30h **Liver Cancer**

Massimo Colombo, MD - IRCCS Cà Granda Ospedale Maggiore Policlinico, Spain

17.45h **Viral Co-Infection**

Mark Nelson, MD, FRCP - Chelsea and Westminster Hospital, UK

18.00h Discussion

18.30h Welcome Reception and Workshop Dinner

SATURDAY 5 DECEMBER

Session 4: Treatment Around the World (Clin. Case based)

09.00h **Patients Assessed in Germany**

Heiner Wedemeyer, MD - Medical School Hannover, Germany

09.15h **Patients in the US**

Fred Poordad, MD - The Texas Liver Institute, USA

09.30h **Patients in Holland**

Rob de Knegt, MD, PhD - Erasmus Medical Center, the Netherlands

09.45h **Patients in Spain**

Maria Buti, MD, PhD - Hospital Valle Hebron, Spain

10.00h Discussion

10.30h Coffee Break

11.00h Industry Symposium

Session 5: Resistance to DAAs

12.00h **Resistance Case and Preventing Resistance**

Stéphane Chevaliez, PharmD, PhD - Hôpital Henri Mondor, Université Paris XII, France

German Hepatitis C Resistance Registry

12.20h **Christophe Sarrazin, MD** - J.W. Goethe University Hospital Frankfurt, Germany

12.40h Discussion

12.50h Closing Remarks

13.00h Lunch

*An application has been made to the EACCME®
for CME accreditation of this event.*